

Iodine-Mediated Domino Oxidative Cyclization: One-Pot Synthesis of 1,3,4-Oxadiazoles via Oxidative Cleavage of C(sp²)-H or C(sp)-H Bond


Yuxing Fan,^{†,‡} Yongqin He,^{†,‡} Xingxing Liu,^{†,‡} Ting Hu,^{†,‡} Haojie Ma,^{†,‡} Xiaodong Yang,^{†,‡} Xinliang Luo,^{†,‡} and Guosheng Huang^{*,†,‡}

[†]State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, Gansu, 730000, P. R. China

[‡]Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, Lanzhou, 730000, P. R. China

Supporting Information

ABSTRACT: An I₂-promoted, metal-free domino protocol for one-pot synthesis of 1,3,4-oxadiazoles has been developed via oxidative cleavage of C(sp²)-H or C(sp)-H bonds, followed by cyclization and deacylation. In this reaction, the use of K₂CO₃ as a base is found to be an essential factor in the cyclization and the C-C bond cleavage. This procedure proceeded smoothly in moderate to high yields with good functional group compatibility.



The domino strategy, due to its applicability to various types of reactions, such as radical,¹ pericyclic,² photochemical,³ and transition-metal-mediated⁴ reactions, has been extensively examined for the synthesis of organic compounds in modern synthetic chemistry.⁵ In the past decade, significant progress has been achieved in developing domino reactions. For example, Jiang and co-workers have developed a series of domino protocols to construct heterocycle compounds.⁶ Wu's group have successfully led to various different compounds by the use of the multiplicative effect of a coupled domino strategy.⁷ In addition, the efficiency and significance of the domino strategy for one-pot synthesis of 2-acylbenzothiazoles from multifunctional substrates were also demonstrated.^{7b} Inspired by these studies, we present a route through domino cyclization for the formation of 1,3,4-oxadiazoles using simple and commercially available reagents via oxidative cleavage of C(sp²)-H or C(sp)-H bonds.

1,3,4-Oxadiazoles are non-naturally occurring five-membered aromatic heterocycles which have been widely used in many compounds with biological and pharmaceutical activities,⁸ such as antifungal, antiviral, and antibacterial properties.⁹ Consequently, a number of methods have been reported for the synthesis of the 1,3,4-oxadiazoles skeleton via oxidative cyclization of *N*-acylhydrazones¹⁰ or the dehydrative cyclization of 1,2-diacylhydrazines.¹¹ In 2013, Chang's group described an I₂-mediated oxidative C-O bond formation for the synthesis of 1,3,4-oxadiazoles from aldehydes and hydrazides (Scheme 1, a).⁹ Subsequently, Wu's group demonstrated a direct annulation of hydrazides to 1,3,4-oxadiazoles via oxidative C(CO)-C(methyl) bond cleavage of methyl ketones (Scheme 1, b),¹² where a wide range of ketones and hydrazides were used as substrates, showing good functional group tolerance and high selectivity. Furthermore, Cu-catalyzed decarboxylative coupling domino reaction for the formation of 2-(1,3,4-

oxadiazol-2-yl) anilines derivatives¹³ was disclosed. However, to our knowledge, I₂-mediated oxidative cyclization for the synthesis of 1,3,4-oxadiazoles from hydrazides and styrene or phenyl acetylene has not yet been reported. Herein, we choose hydrazides and styrene or phenyl acetylene derivatives as the substrates to synthesize 1,3,4-oxadiazoles in the presence of O₂ as the oxidant and K₂CO₃ as the base, achieving the desired products in moderate to good yields.

Initial investigation was conducted by employing reaction of 2a (0.2 mmol) with 1a (0.6 mmol) in the presence of I₂ (0.5 mmol), and K₂CO₃ (0.6 mmol) in DMSO (2.0 mL) under air at 120 °C for 8 h, resulting in 6% yield of 3aa (Table 1, entry 1). To identify the appropriate conditions for the reaction, first, various oxidants were examined, such as TBHP, DDQ, IBX, PhI(OAc)₂, and dioxygen (1 atm). These results illustrated that dioxygen displayed the best ability in this transformation, and a 34% yield of 3aa was obtained (Table 1, entries 2–6). Meanwhile, the yield of side product 4aa was also increased to 50% when dioxygen (1 atm) was used as the oxidant. In order to improve the yield of 3aa, different bases were tested, including K₂CO₃, NaOH, *t*-BuOK, K₃PO₄, Cs₂CO₃, and NaHCO₃. The results promoted us to use K₂CO₃ to conduct this reaction (Table 1, entries 6–11). After screening the amount of K₂CO₃, we found that the substrate showed the highest activity for this process when 6.0 equiv of K₂CO₃ was added, affording 3aa in 85% yield (Table 1, entry 16). Then, different solvents were also evaluated for this conversion, and DMSO effectively facilitated the reaction. Additionally, changing the amount of iodine did not give better results (Table 1, entries 19–23).


Received: May 13, 2016

Published: July 7, 2016


Scheme 1. Synthetic Approaches to 1,3,4-Oxadiazoles

Previous work


a) Chang's work



b) Wu's work



This work

Table 1. Optimization of the Reaction Conditions^a


entry	oxidant	I ₂ (equiv)	base (equiv)	solvent	yield 3aa ^b /4aa (%)
1 ^c		2.5	K ₂ CO ₃ (3.0)	DMSO	6/38
2 ^d	TBHP	2.5	K ₂ CO ₃ (3.0)	DMSO	17/40
3 ^d	DDQ	2.5	K ₂ CO ₃ (3.0)	DMSO	0/10
4 ^d	IBX	2.5	K ₂ CO ₃ (3.0)	DMSO	10/34
5 ^d	PhI(OAc) ₂	2.5	K ₂ CO ₃ (3.0)	DMSO	7/38
6	O ₂	2.5	K ₂ CO ₃ (3.0)	DMSO	34/50
7	O ₂	2.5	NaOH (3.0)	DMSO	0/0
8	O ₂	2.5	<i>t</i> -BuOK (3.0)	DMSO	0/0
9	O ₂	2.5	K ₃ PO ₄ (3.0)	DMSO	21/65
10	O ₂	2.5	Cs ₂ CO ₃ (3.0)	DMSO	27/40
11	O ₂	2.5	NaHCO ₃ (3.0)	DMSO	0/7
12	O ₂	2.5	K ₂ CO ₃ (1.0)	DMSO	0/0
13	O ₂	2.5	K ₂ CO ₃ (2.0)	DMSO	5/50
14	O ₂	2.5	K ₂ CO ₃ (4.0)	DMSO	68/0
15	O ₂	2.5	K ₂ CO ₃ (5.0)	DMSO	75/0
16	O ₂	2.5	K ₂ CO ₃ (6.0)	DMSO	85/0
17	O ₂	2.5	K ₂ CO ₃ (6.0)	DMF	0/0
18	O ₂	2.5	K ₂ CO ₃ (6.0)	Toluene	0/0
19	O ₂	0.5	K ₂ CO ₃ (6.0)	DMSO	0/0
20	O ₂	1.0	K ₂ CO ₃ (6.0)	DMSO	0/0
21	O ₂	1.5	K ₂ CO ₃ (6.0)	DMSO	41/6
22	O ₂	2.0	K ₂ CO ₃ (6.0)	DMSO	51/8
23	O ₂	3.0	K ₂ CO ₃ (6.0)	DMSO	68/6

^aReaction conditions: **1a** (0.6 mmol), **2a** (0.2 mmol) in DMSO (2.0 mL) at 120 °C for 8 h. Dioxygen (1 atm) was used. ^bYields of isolated products. ^cOpen air. ^dOxidant (1.5 equiv). TBHP = *tert*-butyl hydroperoxide (5.0–6.0 M in decane), DDQ = 2,3-dichloro-5,6-dicyanobenzoquinone, IBX = 2-iodoxybenzoic acid, DMSO = dimethyl sulfoxide, DMF = *N,N*-dimethylformamide.

With the optimized conditions in hand, the reaction scope was tested using styrene (**1a**) with different hydrazides (Table 2). A variety of hydrazides proceeded smoothly to afford the corresponding products in moderate to high yields (31–90%). Various functional groups on the aryl ring of the hydrazides demonstrated that both electron-withdrawing and electron-donating groups, including methyl, *tert*-butyl, methoxy, 3,4-methylenedioxy, fluoro, chloro, and bromo, were compatible well with this reaction (**3aa**–**3am**). 2-Naphthyl hydrazine also exhibited good reactivity to give the desired product (**3an**) in 77% yield. Moreover, heteroaryl hydrazides like furanyl and thienyl hydrazides could undergo the tandem reaction smoothly to receive the expected products **3ao** and **3ap** in

48% and 72% yields. Unexpectedly, when we used pyridyl hydrazide as the substrate, the desired product **3aq** was not detected, but the undeacylative byproduct **4ab** was obtained in 45% yield. In addition, alkyl hydrazides, such as acetohydrazide and valeric acid hydrazide, were also investigated. However, only the acetohydrazide could proceed to afford the undeacylative product **4ac** in 27% yield; the substrate of valetic acid hydrazide failed to accomplish this reaction (**3as** and **4ad**).

Subsequently, we explored the limitations of different hydrazides reacting with phenyl acetylene (**1b**). As expected, we were pleased to find that the reaction of **1b** with a range of hydrazides transformed well under the optimized conditions to


Table 2. Synthesis of 1,3,4-Oxadiazoles from Styrene or Phenyl Acetylene and Hydrazides^a

^aReaction conditions: 2a (0.2 mmol), 1a or 1b (0.6 mmol), I₂ (0.5 mmol), and K₂CO₃ (1.2 mmol) in DMSO (2.0 mL) at 120 °C under dioxygen (1 atm) for 8 h.

give the corresponding 1,3,4-oxadiazole products (Table 2, 3ba–3bp) in 40–83% yields. Disappointingly, pyridyl hydrazide, acetohydrazide, and valeric acid hydrazide did not give the desired products (3bq–3bs).

To further expand the scope of the substrates, various styrene and phenyl acetylene derivatives were carried out under the standard conditions. As shown in Table 3, the results indicated that substituents at different positions of the aryl ring did not affect the efficiency obviously. Further studies proved that either electron-withdrawing or electron-donating groups of 1a and 1b all can be converted to the corresponding products in moderate to good yields (35–86%). Vinylnaphthalene was also tolerated in this transformation to produce the desired 2-phenyl-1,3,4-oxadiazole in 82% yield.

On the basis of the above results and literature reports,^{5a,9,12,14} the proposed mechanism for the synthesis of 1,3,4-oxadiazoles is outlined in Scheme 2. Using 1a or 1b and 2a as model substrates, initially, 1a or 1b is converted into phenacyl iodide (A)^{5a,12,14} through consecutive iodination and

Table 3. Synthesis of 2-Phenyl-1,3,4-oxadiazole from Various Styrene or Phenyl Acetylene and Benzoylhydrazide^a

^aReaction conditions: 2a (0.2 mmol), 1a or 1b (0.6 mmol), I₂ (0.5 mmol), and K₂CO₃ (1.2 mmol) in DMSO (2.0 mL) at 120 °C under dioxygen (1 atm) for 8 h.

oxidation under I₂/O₂; then A is further converted into phenylglyoxal (B)^{5a,12,14} by a subsequent Kornblum oxidation in DMSO.^{7b} Benzoylhydrazide (2a) reacts with B to generate the C-acyl benzoylhydrazone (C).¹² Subsequently, K₂CO₃-promoted oxidative iodination of C gives an iodide intermediate D,^{9,12} which would be converted to E via an S_N2'-type^{9,12} cyclization, with a new C–O bond formed. Consequently, 4aa/4ba is formed through subsequent deprotonation by base.⁹ Finally, 4aa/4ba would go through deacylation to generate the product 3aa/3ba with the aid of K₂CO₃.¹²


In summary, we have developed an I₂-mediated direct oxidative cyclization reaction for the synthesis of substituted 1,3,4-oxadiazoles in a one-pot manner. This procedure employs molecular dioxygen as oxidant and K₂CO₃ as base. In addition, K₂CO₃ plays an important role in the cyclization and deacylation. This reaction system has broad substrate scope, providing a facile pathway for the synthesis of 1,3,4-oxadiazoles.

EXPERIMENTAL SECTION

General Remarks. ¹H NMR spectra were obtained at 400 MHz in CDCl₃ with tetramethylsilane (δ = 0.00 ppm) as an internal standard. ¹³C NMR spectra were recorded at 100 MHz and were calibrated with CDCl₃ (δ = 77.00 ppm). The high-resolution mass spectra (HRMS) were recorded on an FT-ICR mass spectrometer using electrospray ionization (ESI). The HRMS data and melting points for the same compounds that have been prepared by two methods were obtained only by the samples of 3aa–3ap and 4aa–4ac. Products were purified by flash chromatography on 200–300 mesh silica gels. All melting points were determined without correction. Unless otherwise noted, commercially available reagents were used without further purification.

General Procedure for the Synthesis of 3 (3aa/3ba as an Example). A test tube was charged with styrene or phenyl acetylene (0.6 mmol), I₂ (0.5 mmol) in DMSO (2.0 mL). The mixture was stirred at 120 °C for 6 h under 1 atm of dioxygen. After the disappearance of the reactant, then added benzoylhydrazide (0.2 mmol), K₂CO₃ (1.2 mmol), and the mixture was heated at 120 °C for 2 h under 1 atm of dioxygen. Upon completion, the mixture was diluted with water and extracted with EtOAc (3 × 20 mL). The extract was washed with 10% Na₂S₂O₃ solution (w/w), dried over anhydrous Na₂SO₄, and evaporated. The residue was purified by column chromatography on silica gel (petroleum ether/EtOAc = 5:1) to yield the desired product 3aa/3ba.

Scheme 2. Possible Mechanism



2-Phenyl-1,3,4-oxadiazole (3aa). Yellow solid. Yield 85% (24.8 mg). mp 33–34 °C (lit.¹⁵ mp 34–36 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.50 (s, 1H), 8.11–8.07 (m, 2H), 7.59–7.50 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.7, 152.6, 132.0, 129.1, 127.0, 123.4. HRMS (ESI) (*m/z*) calcd for C₈H₆N₂O [M + H]⁺ 147.0553; found 147.0556.

2-(4-(*tert*-Butyl)phenyl)-1,3,4-oxadiazole (3ab). Light yellow solid. Yield 72% (29.1 mg). mp 95–98 °C (lit.¹² mp 94–97 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.46 (s, 1H), 8.04–8.00 (m, 2H), 7.56–7.53 (m, 2H), 1.36 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.8, 155.6, 152.4, 126.9, 126.1, 120.6, 35.0, 31.1. HRMS (ESI) (*m/z*) calcd for C₁₂H₁₄N₂O [M + H]⁺ 203.1179; found 203.1181.

2-(*p*-Tolyl)-1,3,4-oxadiazole (3ac). Light yellow solid. Yield 63% (20.2 mg). mp 148–150 °C (lit.¹² mp 149–151 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.46 (s, 1H), 7.97 (d, *J* = 8.1 Hz, 2H), 7.32 (dd, *J* = 8.0, 0.5 Hz, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.8, 152.3, 142.5, 129.7, 126.9, 120.6, 21.6. HRMS (ESI) (*m/z*) calcd for C₉H₈N₂O [M + H]⁺ 161.0746; found 161.0748.

2-(*m*-Tolyl)-1,3,4-oxadiazole (3ad). Yellow oil. Yield 82% (26.2 mg). ¹H NMR (400 MHz, CDCl₃): δ = 8.48 (s, 1H), 7.92 (s, 1H), 7.88 (d, *J* = 7.4 Hz, 1H), 7.44–7.35 (m, 2H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.9, 152.5, 139.0, 132.8, 129.0, 127.6, 124.2, 123.3, 21.3. HRMS (ESI) (*m/z*) calcd for C₉H₈N₂O [M + H]⁺ 161.0746; found 161.0747.

2-(*o*-Tolyl)-1,3,4-oxadiazole (3ae). Yellow oil. Yield 90% (28.8 mg). ¹H NMR (400 MHz, CDCl₃): δ = 8.51 (s, 1H), 7.95 (d, *J* = 7.8 Hz, 1H), 7.43 (t, *J* = 7.4 Hz, 1H), 7.34 (dd, *J* = 13.1, 7.0 Hz, 2H), 2.72 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.8, 152.2, 138.5, 131.7, 131.4, 129.0, 126.1, 122.5, 22.0. HRMS (ESI) (*m/z*) calcd for C₉H₈N₂O [M + H]⁺ 161.0746; found 161.0749.

2-(4-Methoxyphenyl)-1,3,4-oxadiazole (3af). Yellow solid. Yield 60% (21.1 mg). mp 55–57 °C (lit.¹⁶ mp 61–62 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.43 (s, 1H), 8.01 (d, *J* = 8.8 Hz, 2H), 7.02 (d, *J* = 8.8 Hz, 2H), 3.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.6, 162.4, 152.1, 128.8, 115.9, 114.5, 55.4. HRMS (ESI) (*m/z*) calcd for C₉H₈N₂O₂ [M + H]⁺ 177.0659; found 177.0661.

2-(3-Methoxyphenyl)-1,3,4-oxadiazole (3ag). Light yellow solid. Yield 74% (26.0 mg). mp 105–107 °C (lit.¹² mp 105–107 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.48 (s, 1H), 7.66–7.60 (m, 2H), 7.42 (t, *J* = 8.0 Hz, 1H), 7.09 (dd, *J* = 8.3, 2.4 Hz, 1H), 3.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.6, 159.9, 152.6, 130.2, 124.5, 119.4, 118.4, 111.7, 55.4. HRMS (ESI) (*m/z*) calcd for C₉H₈N₂O₂ [M + H]⁺ 177.0659; found 177.0660.

2-(2-Methoxyphenyl)-1,3,4-oxadiazole (3ah). Light yellow solid. Yield 31% (11.0 mg). mp 50–52 °C (lit.¹² mp 49–51 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.51 (s, 1H), 7.96 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.56–7.51 (m, 1H), 7.10 (dd, *J* = 12.2, 4.6 Hz, 2H), 3.98 (s, 3H); ¹³C NMR (101 MHz, CDCl₃): δ = 163.4, 157.8, 152.4, 133.3, 130.5, 120.7, 112.4, 111.9, 55.9. HRMS (ESI) (*m/z*) calcd for C₉H₈N₂O₂ [M + H]⁺ 177.0659; found 177.0662.

2-(Benzof[d][1,3]dioxol-5-yl)-1,3,4-oxadiazole (3ai). Light yellow solid. Yield 45% (17.0 mg). mp 146–148 °C (lit.¹² mp 147–149 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.43 (s, 1H), 7.63 (dd, *J* = 8.1, 1.7 Hz, 1H), 7.53 (d, *J* = 1.5 Hz, 1H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.08 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.5, 152.2, 150.8, 148.3, 122.2, 117.2, 108.9, 107.1, 101.9. HRMS (ESI) (*m/z*) calcd for C₉H₆N₂O₃ [M + H]⁺ 191.0451; found 191.0453.

2-(4-Fluorophenyl)-1,3,4-oxadiazole (3aj). Light yellow solid. Yield 61% (20.0 mg). mp 72–74 °C (lit.¹⁷ mp 121.0–122.0 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.48 (s, 1H), 8.11 (dd, *J* = 8.9, 5.2 Hz, 2H), 7.23 (t, *J* = 8.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 165.1 (d, *J* = 223 Hz), 152.6, 129.4 (d, *J* = 8.9 Hz), 119.9 (d, *J* = 3.3 Hz), 116.6, 116.4. HRMS (ESI) (*m/z*) calcd for C₈H₅FN₂O [M + H]⁺ 165.0459; found 165.0460.

2-(4-Chlorophenyl)-1,3,4-oxadiazole (3ak). Light yellow solid. Yield 58% (20.9 mg). mp 134–136 °C (lit.¹⁶ 134–135 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.51 (s, 1H), 8.03 (dd, *J* = 8.6, 2.0 Hz, 2H), 7.51 (dd, *J* = 8.6, 1.9 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 163.9, 152.7, 138.2, 129.4, 128.3, 121.8. HRMS (ESI) (*m/z*) calcd for C₈H₅ClN₂O [M + H]⁺ 181.0163; found 181.0166.

2-(3-Chlorophenyl)-1,3,4-oxadiazole (3al). Light yellow solid. Yield 69% (24.8 mg). mp 79–82 °C (lit.¹⁸ 115.3 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.51 (s, 1H), 8.09 (d, *J* = 1.4 Hz, 1H), 7.99 (dd, *J* = 7.7, 1.1 Hz, 1H), 7.54 (dd, *J* = 5.0, 3.9 Hz, 1H), 7.48 (t, *J* = 7.9 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 163.6, 152.8, 135.2, 132.1, 130.5, 127.1, 125.2, 125.0. HRMS (ESI) (*m/z*) calcd for C₈H₅ClN₂O [M + H]⁺ 181.0163; found 181.0167.

2-(4-Bromophenyl)-1,3,4-oxadiazole (3am). Light yellow solid. Yield 71% (32.0 mg). mp 139–142 °C (lit.¹² mp 140–143 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.51 (s, 1H), 7.95 (d, *J* = 8.6 Hz, 2H), 7.67 (d, *J* = 8.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.0, 152.7, 132.4, 128.4, 126.7, 122.2. HRMS (ESI) (*m/z*) calcd for C₈H₅BrN₂O [M + H]⁺ 224.9658; found 224.9662.

2-(Naphthalen-2-yl)-1,3,4-oxadiazole (3an). Light yellow solid. Yield 77% (30.2 mg). mp 58–60 °C (lit.¹⁹ mp 60–62 °C); ¹H NMR (400 MHz, CDCl₃): δ = 8.57 (s, 1H), 8.52 (s, 1H), 8.16–8.12 (m,

1H), 7.95 (dd, $J = 7.0, 4.5$ Hz, 2H), 7.89 (d, $J = 7.6$ Hz, 1H), 7.62–7.54 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.9, 152.6, 134.7, 132.7, 129.0, 128.8, 128.0, 127.9, 127.6, 127.1, 123.1, 120.6$. HRMS (ESI) (m/z) calcd for $\text{C}_{12}\text{H}_8\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 197.0710; found 197.0714.

2-(Furan-2-yl)-1,3,4-oxadiazole (3ao). Yellow oil. Yield 48% (13.0 mg). ^1H NMR (400 MHz, CDCl_3): $\delta = 8.45$ (s, 1H), 7.68 (d, $J = 1.0$ Hz, 1H), 7.22 (d, $J = 3.5$ Hz, 1H), 6.63 (dd, $J = 3.5, 1.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 157.5, 151.8, 146.0, 139.0, 114.6, 112.2$. HRMS (ESI) (m/z) calcd for $\text{C}_6\text{H}_4\text{N}_2\text{O}_2$ [$\text{M} + \text{H}$] $^+$ 137.0346; found 137.0349.

2-(Thiophen-2-yl)-1,3,4-oxadiazole (3ap). Yellow solid. Yield 72% (21.9 mg). mp 150–152 °C (lit.¹² mp 151–154 °C); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.45$ (s, 1H), 7.80 (dd, $J = 2.9, 2.0$ Hz, 1H), 7.59 (dd, $J = 5.0, 1.2$ Hz, 1H), 7.19 (ddd, $J = 5.1, 3.7, 1.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 160.9, 151.9, 130.5, 130.1, 128.1, 124.5$. HRMS (ESI) (m/z) calcd for $\text{C}_6\text{H}_4\text{N}_2\text{OS}$ [$\text{M} + \text{H}$] $^+$ 153.0117; found 153.0119.

Phenyl(5-phenyl-1,3,4-oxadiazol-2-yl)methanone (4aa). Light yellow solid. Yield 65% (33.0 mg). mp 95–97 °C (lit.¹² mp 95–97 °C); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.62$ – 8.55 (m, 2H), 8.28–8.20 (m, 2H), 7.72 (dd, $J = 10.5, 4.3$ Hz, 1H), 7.65–7.54 (m, 5H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 177.6, 166.0, 160.9, 134.9, 134.3, 132.9, 130.9, 129.2, 128.8, 127.8, 122.8$. HRMS (ESI) (m/z) calcd for $\text{C}_{15}\text{H}_{10}\text{N}_2\text{O}_2$ [$\text{M} + \text{H}$] $^+$ 251.0815; found 251.0819.

Phenyl(5-(pyridine-4-yl)-1,3,4-oxadiazol-2-yl)methanone (4ab). Light yellow solid. Yield 45% (23.0 mg). mp 148–150 °C (lit.¹² mp 148–151 °C); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.89$ (d, $J = 5.9$ Hz, 2H), 8.60–8.54 (m, 2H), 8.07 (dd, $J = 4.5, 1.5$ Hz, 2H), 7.73 (t, $J = 7.4$ Hz, 1H), 7.59 (t, $J = 7.8$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 177.2, 164.0, 161.2, 151.0, 135.2, 133.9, 130.9, 130.0, 128.9, 120.9$. HRMS (ESI) (m/z) calcd for $\text{C}_{14}\text{H}_9\text{N}_3\text{O}_2$ [$\text{M} + \text{H}$] $^+$ 252.0732; found 252.0736.

(5-Methyl-1,3,4-oxadiazol-2-yl)(phenyl)methanone (4ac). Brown solid. Yield 27% (10.0 mg). mp 107–109 °C (lit.¹² mp 106–109 °C); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.53$ (d, $J = 7.4$ Hz, 2H), 7.70 (t, $J = 7.4$ Hz, 1H), 7.56 (t, $J = 7.8$ Hz, 2H), 2.70 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 177.6, 165.7, 161.4, 134.8, 134.0, 130.9, 128.7, 11.1$. HRMS (ESI) (m/z) calcd for $\text{C}_{10}\text{H}_8\text{N}_2\text{O}_2$ [$\text{M} + \text{H}$] $^+$ 189.0659; found 189.0660.

2-Phenyl-1,3,4-oxadiazole (3ba). Yellow solid. Yield 75% (21.9 mg). mp 33–34 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.47$ (s, 1H), 8.09 (dd, $J = 8.1, 1.6$ Hz, 2H), 7.58–7.51 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.8, 152.6, 132.0, 129.1, 127.1, 123.5$. HRMS (ESI) (m/z) calcd for $\text{C}_8\text{H}_6\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 147.0553; found 147.0556.

2-(4-(tert-Butyl)phenyl)-1,3,4-oxadiazole (3bb). Light yellow solid. Yield 75% (30.3 mg). mp 95–98 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.45$ (s, 1H), 8.01 (d, $J = 8.5$ Hz, 2H), 7.54 (d, $J = 8.5$ Hz, 2H), 1.36 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.8, 155.6, 152.4, 126.9, 126.1, 120.7, 35.1, 31.1$. HRMS (ESI) (m/z) calcd for $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 203.1179; found 203.1181.

2-(*p*-Tolyl)-1,3,4-oxadiazole (3bc). Light yellow solid. Yield 75% (24.0 mg). mp 148–150 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.45$ (s, 1H), 7.96 (d, $J = 8.2$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 2H), 2.43 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.8, 152.3, 142.5, 129.7, 127.0, 120.7, 21.6$. HRMS (ESI) (m/z) calcd for $\text{C}_9\text{H}_8\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 161.0746; found 161.0748.

2-(*m*-Tolyl)-1,3,4-oxadiazole (3bd). Yellow oil. Yield 75% (24.0 mg). ^1H NMR (400 MHz, CDCl_3): $\delta = 8.46$ (s, 1H), 7.92 (s, 1H), 7.87 (d, $J = 7.4$ Hz, 1H), 7.43–7.34 (m, 2H), 2.44 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.9, 152.5, 139.0, 132.8, 129.0, 127.6, 124.2, 123.3, 21.3$. HRMS (ESI) (m/z) calcd for $\text{C}_9\text{H}_8\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 161.0746; found 161.0747.

2-(*o*-Tolyl)-1,3,4-oxadiazole (3be). Yellow oil. Yield 81% (25.9 mg). ^1H NMR (400 MHz, CDCl_3): $\delta = 8.50$ (s, 1H), 7.95 (d, $J = 7.9$ Hz, 1H), 7.43 (dd, $J = 10.8, 4.2$ Hz, 1H), 7.34 (dd, $J = 13.6, 7.2$ Hz, 2H), 2.72 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.9, 152.2, 138.6, 131.7, 131.4, 129.1, 126.2, 122.6, 22.0$. HRMS (ESI) (m/z) calcd for $\text{C}_9\text{H}_8\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 161.0746; found 161.0749.

2-(4-Methoxyphenyl)-1,3,4-oxadiazole (3bf). Yellow solid. Yield 71% (25.0 mg). mp 55–57 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.43$ (s, 1H), 8.02 (d, $J = 8.8$ Hz, 2H), 7.02 (d, $J = 8.8$ Hz, 2H), 3.89 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.6, 162.4, 152.1, 128.8, 115.9, 114.5, 55.4$. HRMS (ESI) (m/z) calcd for $\text{C}_9\text{H}_8\text{N}_2\text{O}_2$ [$\text{M} + \text{H}$] $^+$ 177.0659; found 177.0661.

2-(3-Methoxyphenyl)-1,3,4-oxadiazole (3bg). Light yellow solid. Yield 60% (21.1 mg). mp 105–107 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.48$ (s, 1H), 7.66–7.60 (m, 2H), 7.42 (t, $J = 8.0$ Hz, 1H), 7.11–7.07 (m, 1H), 3.88 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.6, 159.9, 152.6, 130.2, 124.5, 119.4, 118.4, 111.7, 55.4$. HRMS (ESI) (m/z) calcd for $\text{C}_9\text{H}_8\text{N}_2\text{O}_2$ [$\text{M} + \text{H}$] $^+$ 177.0659; found 177.0660.

2-(2-Methoxyphenyl)-1,3,4-oxadiazole (3bh). Light yellow solid. Yield 40% (14.1 mg). mp 50–52 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.49$ (s, 1H), 7.96 (d, $J = 7.7$ Hz, 1H), 7.56–7.50 (m, 1H), 7.09 (t, $J = 8.1$ Hz, 2H), 3.97 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 163.4, 157.8, 152.4, 133.3, 130.5, 120.7, 112.4, 111.9, 55.9$. HRMS (ESI) (m/z) calcd for $\text{C}_9\text{H}_8\text{N}_2\text{O}_2$ [$\text{M} + \text{H}$] $^+$ 177.0659; found 177.0662.

2-(Benzofur[1,3]dioxol-5-yl)-1,3,4-oxadiazole (3bi). Light yellow solid. Yield 68% (25.6 mg). mp 146–148 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.43$ (s, 1H), 7.62 (dd, $J = 8.2, 1.7$ Hz, 1H), 7.52 (d, $J = 1.6$ Hz, 1H), 6.92 (d, $J = 8.2$ Hz, 1H), 6.07 (s, 2H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.4, 152.2, 150.8, 148.3, 122.2, 117.2, 108.8, 107.1, 101.8$. HRMS (ESI) (m/z) calcd for $\text{C}_9\text{H}_6\text{N}_2\text{O}_3$ [$\text{M} + \text{H}$] $^+$ 191.0451; found 191.0453.

2-(4-Fluorophenyl)-1,3,4-oxadiazole (3bj). Light yellow solid. Yield 55% (18.0 mg). mp 72–74 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.48$ (s, 3H), 8.11 (dd, $J = 8.9, 5.2$ Hz, 6H), 7.24 (dd, $J = 16.4, 7.9$ Hz, 7H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 165.1$ (d, $J = 223$ Hz), 152.6, 129.4 (d, $J = 8.9$ Hz), 119.9 (d, $J = 3.3$ Hz), 116.6, 116.4. HRMS (ESI) (m/z) calcd for $\text{C}_8\text{H}_3\text{FN}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 165.0459; found 165.0460.

2-(4-Chlorophenyl)-1,3,4-oxadiazole (3bk). Light yellow solid. Yield 83% (29.9 mg). mp 134–136 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.49$ (s, 1H), 8.03 (d, $J = 8.6$ Hz, 2H), 7.51 (d, $J = 8.6$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.0, 152.7, 138.3, 129.5, 128.3, 121.9$. HRMS (ESI) (m/z) calcd for $\text{C}_8\text{H}_3\text{ClN}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 181.0163; found 181.0166.

2-(3-Chlorophenyl)-1,3,4-oxadiazole (3bl). Light yellow solid. Yield 58% (20.9 mg). mp 79–82 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.50$ (s, 1H), 8.08 (s, 1H), 7.99 (d, $J = 7.7$ Hz, 1H), 7.54 (d, $J = 8.1$ Hz, 1H), 7.47 (t, $J = 7.9$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 163.6, 152.8, 135.3, 132.0, 130.5, 127.0, 125.2, 125.1$. HRMS (ESI) (m/z) calcd for $\text{C}_8\text{H}_3\text{ClN}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 181.0163; found 181.0167.

2-(4-Bromophenyl)-1,3,4-oxadiazole (3bm). Light yellow solid. Yield 62% (27.9 mg). mp 139–142 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.50$ (s, 1H), 7.95 (dd, $J = 8.4, 1.2$ Hz, 2H), 7.69–7.63 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.0, 152.7, 132.4, 128.4, 126.7, 122.3$. HRMS (ESI) (m/z) calcd for $\text{C}_8\text{H}_3\text{BrN}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 224.9658; found 224.9662.

2-(Naphthalen-2-yl)-1,3,4-oxadiazole (3bn). Light yellow solid. Yield 63% (24.7 mg). mp 58–60 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.53$ (s, 1H), 8.51 (s, 1H), 8.11 (d, $J = 8.6$ Hz, 1H), 7.93 (d, $J = 9.3$ Hz, 2H), 7.86 (d, $J = 7.5$ Hz, 1H), 7.60–7.51 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.8, 152.6, 134.6, 132.6, 129.0, 128.8, 128.0, 127.8, 127.5, 127.0, 123.0, 120.6$. HRMS (ESI) (m/z) calcd for $\text{C}_{12}\text{H}_8\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$ 197.0710; found 197.0714.

2-(Furan-2-yl)-1,3,4-oxadiazole (3bo). Yellow oil. Yield 40% (10.8 mg). ^1H NMR (400 MHz, CDCl_3): $\delta = 8.45$ (s, 1H), 7.68 (d, $J = 1.0$ Hz, 1H), 7.22 (d, $J = 3.5$ Hz, 1H), 6.63 (dd, $J = 3.5, 1.8$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 157.5, 151.8, 146.0, 139.0, 114.6, 112.2$. HRMS (ESI) (m/z) calcd for $\text{C}_6\text{H}_4\text{N}_2\text{O}_2$ [$\text{M} + \text{H}$] $^+$ 137.0346; found 137.0349.

2-(Thiophen-2-yl)-1,3,4-oxadiazole (3bp). Yellow solid. Yield 67% (20.4 mg). mp 150–152 °C (lit.¹² mp 151–154 °C); ^1H NMR (400 MHz, CDCl_3): $\delta = 8.42$ (s, 1H), 7.80 (dd, $J = 3.7, 1.0$ Hz, 1H), 7.58 (dd, $J = 5.0, 1.0$ Hz, 1H), 7.19 (dd, $J = 5.0, 3.8$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 160.9, 151.9, 130.5, 130.2, 128.2, 124.6$. HRMS (ESI) (m/z) calcd for $\text{C}_6\text{H}_4\text{N}_2\text{OS}$ [$\text{M} + \text{H}$] $^+$ 153.0117; found 153.0119.

Phenyl(5-phenyl-1,3,4-oxadiazol-2-yl)methanone (4ba). Light yellow solid. Yield 55% (27.9 mg). mp 95–97 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.58 (d, J = 7.2 Hz, 2H), 8.24 (d, J = 6.9 Hz, 2H), 7.74–7.69 (m, 1H), 7.65–7.54 (m, 5H). ¹³C NMR (100 MHz, CDCl₃): δ = 177.6, 166.0, 160.9, 134.9, 134.3, 132.8, 131.0, 129.3, 128.8, 127.8, 122.8. HRMS (ESI) (*m/z*) calcd for C₁₅H₁₀N₂O₂ [M + H]⁺ 251.0815; found 251.0819.

Phenyl(5-(pyridine-4-yl)-1,3,4-oxadiazol-2-yl)methanone (4bb). Light yellow solid. Yield 48% (24.5 mg). mp 148–150 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.90 (d, J = 6.0 Hz, 2H), 8.57 (d, J = 7.3 Hz, 2H), 8.09 (d, J = 6.1 Hz, 2H), 7.74 (t, J = 7.4 Hz, 1H), 7.60 (t, J = 7.8 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 177.3, 164.1, 161.2, 151.0, 135.2, 134.0, 131.0, 130.1, 128.9, 121.0. HRMS (ESI) (*m/z*) calcd for C₁₄H₉N₃O₂ [M + H]⁺ 252.0732; found 252.0736.

(5-Methyl-1,3,4-oxadiazol-2-yl)(phenyl)methanone (4bc). Brown solid. Yield 32% (11.9 mg); mp 107–109 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.53 (dd, J = 8.4, 1.2 Hz, 2H), 7.72–7.68 (m, 1H), 7.56 (t, J = 7.8 Hz, 2H), 2.70 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 177.7, 165.8, 161.4, 134.9, 134.1, 130.9, 128.8, 11.2. HRMS (ESI) (*m/z*) calcd for C₁₀H₈N₂O₂ [M + H]⁺ 189.0659; found 189.0660.

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b01135.

Copies of ¹H and ¹³C NMR spectra for all reaction products (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*Fax: +86 0931 8912596. E-mail: hgs@lzu.edu.cn.

Notes

The authors declare no competing financial interest.

■ REFERENCES

- (1) Sebren, L. J.; Devery, J. J.; Stephenson, C. R. *ACS Catal.* **2014**, *4*, 703.
- (2) Poulin, J.; Grise-Bard, C. M.; Barriault, L. *Chem. Soc. Rev.* **2009**, *38*, 3092.
- (3) Horvat, M.; Görner, H.; Warzecha, K. D.; Neudörfl, J.; Griesbeck, A. G.; Mlinarić-Majerski, K.; Basarić, N. *J. Org. Chem.* **2009**, *74*, 8219.
- (4) Wang, D. C.; Niu, H. Y.; Xie, M. S.; Qu, G. R.; Wang, H. X.; Guo, H. M. *Org. Lett.* **2014**, *16*, 262.
- (5) (a) Jiang, H. F.; Huang, H. W.; Cao, H.; Qi, C. R. *Org. Lett.* **2010**, *12*, 5561. (b) Enders, D.; Wang, C.; Bats, J. W. *Angew. Chem.* **2008**, *120*, 7649.
- (6) (a) Cao, H.; Jiang, H. F.; Yao, W. J.; Liu, X. H. *Org. Lett.* **2009**, *11*, 1931. (b) Liu, W. B.; Jiang, H. F.; Zhang, M.; Qi, C. R. *J. Org. Chem.* **2010**, *75*, 966. (c) Cao, H.; Jiang, H. F.; Mai, R. H.; Zhu, S. F.; Qi, C. R. *Adv. Synth. Catal.* **2010**, *352*, 143. (d) Wang, A. Z.; Jiang, H. F. *J. Org. Chem.* **2010**, *75*, 2321.
- (7) (a) Xue, W. J.; Guo, Y. Q.; Gao, F. F.; Li, H. Z.; Wu, A. X. *Org. Lett.* **2013**, *15*, 890. (b) Zhu, Y. P.; Jia, F. C.; Liu, M. C.; Wu, A. X. *Org. Lett.* **2012**, *14*, 4414. (c) Zhu, Y. P.; Lian, M.; Jia, F. C.; Liu, M. C.; Yuan, J. J.; Gao, Q. H.; Wu, A. X. *Chem. Commun.* **2012**, *48*, 9086. (d) Zhu, Y. P.; Gao, Q. H.; Lian, M.; Yuan, J. J.; Liu, M. C.; Zhao, Q.; Yang, Y.; Wu, A. X. *Chem. Commun.* **2011**, *47*, 12700.
- (8) (a) Sharma, S.; Sharma, P. K.; Kumar, N.; Dudhe, R. *Der Pharma Chem.* **2010**, *2*, 253. (b) Bhatia, S.; Gupta, M. *J. Chem. Pharm. Res.* **2011**, *3*, 137. (c) Li, Z.; Zhan, P.; Liu, X. *Mini-Rev. Med. Chem.* **2011**, *11*, 1130. (d) Sahu, V. K. R.; Singh, A. K.; Yadav, D. *Int. J. ChemTech Res.* **2011**, *3*, 1362. (e) Singh, A. K.; Sahu, V. K. R.; Yadav, D. *Int. J. Pharma Sci. Res.* **2011**, *2*, 135. (f) Khalilullah, H.; Ahsan, M. J.; Hedaitullah, M.; Khan, S.; Ahmed, B. *Mini-Rev. Med. Chem.* **2012**, *12*, 789.
- (9) Yu, W. Q.; Huang, G.; Zhang, Y. T.; Liu, H. X.; Dong, L. H.; Yu, X. J.; Li, Y. J.; Chang, J. B. *J. Org. Chem.* **2013**, *78*, 10337.

- (10) (a) Guin, S.; Ghosh, T.; Rout, S. K.; Banerjee, A.; Patel, B. K. *Org. Lett.* **2011**, *13*, 5976. (b) Niu, P. F.; Kang, J. F.; Tian, X. H.; Song, L. N.; Liu, H. X.; Wu, J.; Yu, W. Q.; Chang, J. B. *J. Org. Chem.* **2015**, *80*, 1018. (c) Shang, Z. H.; Chu, Q.; Tan, S. *Synthesis* **2015**, *47*, 1032.
- (11) Pouliot, M. F.; Angers, L.; Hamel, J. D.; Paquin, J. F. *Org. Biomol. Chem.* **2012**, *10*, 988.
- (12) Gao, Q. H.; Liu, S.; Wu, X.; Zhang, J. J.; Wu, A. X. *Org. Lett.* **2015**, *17*, 2960.
- (13) Xu, C.; Jia, F. C.; Cai, Q.; Li, D. K.; Zhou, Z. W.; Wu, A. X. *Chem. Commun.* **2015**, *51*, 6629.
- (14) (a) Viswanadham, K. K. D. R.; Reddy, M. P.; Sathyanarayana, P.; Ravi, O.; Kant, R.; Bathula, S. R. *Chem. Commun.* **2014**, *50*, 13517. (b) Hu, T.; Yan, H.; Liu, X. X.; Wu, Z. Y.; Fan, Y. X.; Huang, J.; Huang, G. S. *Synlett* **2015**, *26*, 2866. (c) Xiang, J. C.; Wang, J. G.; Wang, M.; Meng, X. G.; Wu, A. X. *Tetrahedron* **2014**, *70*, 7470. (d) Xu, W.; Kloeckner, U.; Nachtsheim, B. J. *J. Org. Chem.* **2013**, *78*, 6065.
- (15) Katritzky, A. R.; Huang, T. B.; Voronkov, M. V. *J. Org. Chem.* **2000**, *65*, 2246.
- (16) Gnanasekaran, K. K.; Nammalwar, B.; Murie, M.; Bunce, R. A. *Tetrahedron Lett.* **2014**, *55*, 6776.
- (17) Suresh, D.; Kanagaraj, K.; Pitchumani, K. *Tetrahedron Lett.* **2014**, *55*, 3678.
- (18) Rouhani, M.; Ramazani, A.; Joo, S. W. *Ultrason. Sonochem.* **2014**, *21*, 262.
- (19) Kawano, T.; Hirano, K.; Satoh, T.; Miura, M. *J. Am. Chem. Soc.* **2010**, *132*, 6900.